

Neurological comorbidities in migraine and associated white matter hyperintensities in patients undergoing MRI.

¹Fasal Ahmad Rather, Department of Medicine, Govt. Medical College, Srinagar.

³Omar Farooq, Professor, Neurologist, Department of Medicine, Govt. Medical College, Srinagar.

¹Irfan Ahmad Dar, Radiology, Department of Medicine, Govt. Medical College, Srinagar.

³Shabir Ahmad Bhat, Radiology, Department of Medicine, Govt. Medical College, Srinagar.

²Zahid Iqbal Shah, PHD Scholar, Department of Medicine, Govt. Medical College, Srinagar.

¹Pandem Bhargavi, Department of Medicine, Govt. Medical College, Srinagar.

¹Shabir Ahmad Rather, Department of Medicine, Govt. Medical College, Srinagar.

¹Ishfaq Majeed, Department of Medicine, Govt. Medical College, Srinagar.

¹Pratab Sharma, Department of Medicine, Govt. Medical College, Srinagar.

¹Rozia Bhukhari, Department of Medicine, Govt. Medical College, Srinagar.

¹Humayun, Department of Medicine, Govt. Medical College, Srinagar.

Corresponding Author: Omar Farooq, Professor, Neurologist, Department of Medicine, Govt. Medical College, Srinagar.

Citation this Article: Fasal Ahmad Rather, Omar Farooq, Irfan Ahmad Dar, Shabir Ahmad Bhat, Zahid Iqbal Shah, Pandem Bhargavi, Shabir Ahmad Rather, Ishfaq Majeed, Pratab Sharma, Rozia Bhukhari, Humayun, “Neurological comorbidities in migraine and associated white matter hyperintensities in patients undergoing MRI”, IJMSIR- February - 2023, Vol – 8, Issue - 1, P. No. 180 – 193.

Type of Publication: Original Research Article

Conflicts of Interest: Nil

Abstract

Background: Migraine is the most common disability causing headache. Migraine patients have frequently associated white matter Hyperintensities on Brain MRI. In this study we aimed to establish a relationship between clinical profile of Migraine and white matter Hyper intensities.

Methods: Cross sectional analytical study of Migraine patients was conducted in GMC Srinagar, Department of Medicine for two years. Detailed history, Examination and MRI Brain of patients was done.

Results: Out of 90 patients, 75.6% were females and 24.4% were males, mean age of patients was 34 years, 46.7 % had white matter Hyper intensities, while 53.3 %

of patients didn't had any presence of white matter Hyper intensities. We tried to establish a relation between clinical profile of Migraine and White matter Hyper intensities.

Among the patients with vomiting, 80% had white matter hyperintensities. 58.8% of the patients with severe headache had white matter hyper intensities while as it was absent in 41.2% of the patients. 69.2% of the patients with more than one attack per week had white matter hyperintensities while as 30.8% of the patients had no white matter hyperintensities.

Conclusions: Our study concludes that age, duration of migraine, intensity of pain, nausea/vomiting, frequency of attacks, duration of attacks, intensity of migraine as

per MIGSEV scale have a role in the presence and absence white matter hyper intensities. Our study found that the presence of white matter hyper intensities has more chances in patients who are aged, have frequent attacks of migraine, have intense pain, feel highly nauseated, have longer duration of attacks and have Grade III migraine on MIGSEV scale.

Keywords: Migraine, white matter Hyper intensities, MRI Brain, MiGSEV scale

Introduction

Migraine is a ubiquitous neurologic disorder that is estimated to affect approximately 1 billion people worldwide, predominantly females¹. Migraine is the second most prevalent neurologic disorder (after tension-type headache), with a female-to-male ratio of 3:1 and an estimated 1-year prevalence of approximately 15% in the general population¹.

The prevalence peaks between the ages of 35 and 39 years, and about 75% of affected persons report the onset of migraine before the age of 35 years^{1,2}. The diagnosis is based on clinical criteria provided by the International Classification of Headache Disorders, 3rd edition (ICHD-3)³. Broad clinical features suggestive of migraine are recurrent headache attacks of moderate-to-severe pain intensity, with a duration of 4 to 72 hours³.

A diagnosis of migraine should be considered if a typical attack of head pain is unilateral, pulsating, and aggravated by physical activity³. Common accompanying symptoms are nausea, vomiting, photophobia, and phonophobia³. Some persons report that the migraine is preceded by an aura, which is characterized by reversible focal neurologic symptoms, typically comprising visual or hemisensory disturbances³.

The trigemino vascular system is considered to be the anatomical and physiological substrate from which nociceptive transmission originates and yields the

perception of migraine pain⁴. In 1984, Moskowitz proposed that migraine initiation depends on activation and sensitization of first-order trigemino vascular neurons. The afferent fibers of these neurons innervate the meninges and its vessels and also project to structures in the central nervous system⁵. Activation of these neurons releases vasoactive peptides and induces local inflammatory reactions⁵.

This process, in turn, sensitizes and discharges second-order neurons in the brain stem and then third-order neurons in the thalamus⁴, until ultimately nociceptive impulses reach the somatosensory and other cortical areas that are involved in pain perception⁴. Pharmacologic therapy, the mainstay of treatment, includes initial and preventive medications, with nonpharmacologic therapies used as adjuncts to medication⁶.

Migraine sometimes is associated with White Matter Hyperintensities (WMHs)⁷, which are hyperintense brain lesions in T2-weighted and Fluid-Attenuated Inversion Recovery (FLAIR) images⁸.

The relation between WMHs and the clinical features of migraine is still unclear. Some studies suggested that WMHs are more frequent in migraine patients with more headache attacks⁷. Other studies demonstrated that disease duration was associated with WMHs in migraine patients⁹. One study found an association between WMHs and the older age of patients¹⁰.

Other studies have reported that WMHs are not associated with disease duration or attack frequency¹¹. Understanding the relation between WMHs and migraine may help patient management¹². Previous population-based studies have indicated that WMHs in migraine are not associated with stroke or the decline in cognitive function¹³⁻¹⁴. Eggers proposed that WMHs might be caused by multiple micro emboli, which are induced by

platelet aggregation abnormalities usually observed in migraine patients¹⁵. This supports that WMHs may reflect an abnormal internal environment in patients. A previous study has shown that hyper homo cysteine Mia is associated with migraine, especially migraine with aura¹⁶.

A high level of homocysteine is associated with vascular insults such as thrombosis, atherosclerosis, and ischemic diseases, such as myocardial infarction and ischemic stroke^{17, 18, 19}.

Hyper homo cysteine Mia may stimulate the initiation of migraine attacks through changes in pain threshold²⁰. A previous study revealed that higher levels of homo cysteine are related to higher severity and frequency of migraine attacks²¹, whereas others showed no relationship between homo cysteine levels and frequency of these attacks²². Association between elevated serum homo cysteine level and WMHs have been documented in several studies^{23, 24, 25}. This study was aimed to assess the frequency of migraine attacks and duration of migraine in years and WMHs.

Material and methods

This cross-sectional study was conducted in post graduate department of medicine Government Medical College Srinagar after obtaining ethical clearance from the institutional ethical committee.

patients fulfilling the inclusion and exclusion criteria were included after obtaining proper informed consent in local language. This study was completed within the span of 2 years

Inclusion criteria

All patients fulfilling the ICHD-3 criteria for migraine were included.

1. At least five attacks fulfilling 2-4
2. headache attacks lasting 4-72 hours
3. Headache has two of following four characteristics.

- a) Unilateral
 - b) Pulsating
 - c) Moderate or severe in intensity
 - d) Aggravated by physical activity
4. During headache at least one of the following.
 - a) Nausea and or vomiting
 - b) Photo phobia and phonophobia

We also included patients with history suggestive of vascular, demyelinating, infection or other disorders with CNS pathology and patients with focal neurologic deficits, all having underlying migraine.

Exclusion criteria

Patients with hyper tension, dyslipidemia, diabetes mellitus, cardiac disease, history suggestive of any malignancy.

Study method

Participants were defined as having migraine if they advocated a lifetime history of headaches that;


1. Lasted 4 or more hours in duration.
2. Were characterized as throbbing, pounding or pulsating in nature or that were unilateral in locations.
3. Were accompanied by nausea, vomiting or sensitivity to light or sound and
4. Constituted one or more years with history of such headaches. Headaches lasting at least 4 hours but not meeting all of the other criteria were defined as non-migraine headaches. Relation between white matter hyper intensities and clinical profile of migraine patients was established.

Results and observation

Table 1: Gender Break-up of Patients.

| Gender | Frequency | Percentage |
|--------|-----------|------------|
| Males | 22 | 24.44% |
| Female | 68 | 75.55% |

Graph 1:



Graph 3:



Table 2: Migraine and Aura.

| Aura in Patients | |
|------------------|----|
| Absent | 50 |
| Present | 40 |
| Total | 90 |

Table 4: Duration of migraine (in Years)

| Duration of Migraine (years) | Frequency |
|------------------------------|-----------|
| 2 | 6 |
| 3 | 8 |
| 4 | 12 |
| 5 | 6 |
| 6 | 8 |
| 7 | 8 |
| 8 | 10 |
| 9 | 12 |
| 10 | 12 |
| 12 | 8 |
| Total | 90 |

Graph 2:




Table 3: Age wise break-up of patients.

| Age wise breakup of patients | |
|------------------------------|-----------|
| Age Group in Years | Frequency |
| 10-20 | 2 |
| 21-30 | 36 |
| 31-40 | 34 |
| 41-50 | 18 |
| Total | 90 |

Graph 4:




Table 5: Migraine and Nausea/Vomiting.

| Nausea | |
|-----------------|-----------|
| Types of Nausea | Frequency |
| Mild | 30 |
| Intense | 40 |
| None | 10 |

| | |
|----------|----|
| Vomiting | 10 |
| Total | 90 |

Graph 5:




Table 6: Migraine and Intensity of pain

| Pain | |
|-------------------|-----------|
| Intensity of pain | Frequency |
| Intense | 24 |
| Very intense | 24 |
| Moderate | 22 |
| Mild | 20 |
| Total | 90 |

Graph 6:




Table 7: migraine and Duration of Attack (in hours)

| Duration Of Attack (in hours) | No. of Patients |
|-------------------------------|-----------------|
| > 24 hours | 34 |
| 04-12 hours | 20 |

| | |
|---------------|----|
| 12 - 24 hours | 36 |
| Total | 90 |

Graph 7:




Table 8: Migraine and Frequency of Attacks

| Frequency of Attacks | Frequency |
|----------------------|-----------|
| <1/ year | 0 |
| <04/ year | 12 |
| >1 / week | 26 |
| 1/ week | 20 |
| 1-2 / month | 16 |
| 5 - 10 / year | 16 |
| Total | 90 |

Graph 8:




Table 9: Migraine and WMH in patients of Nausea/ Vomiting.

| Nausea | Discrete T2/FLAIR hyperintensities | | |
|--------|------------------------------------|---------|--------|
| | Total | Present | Absent |
| Mild | 48 | 14 | 34 |

| | | | |
|----------|----|----|----|
| Intense | 28 | 20 | 08 |
| None | 04 | 0 | 04 |
| Vomiting | 10 | 08 | 02 |
| Total | 90 | 42 | 48 |

Graph 9:




Table 10: Duration of Migraine and WMH

| Duration of migraine (years) | Discrete T2/ FLAIR hyperintensities | | |
|------------------------------|-------------------------------------|---------|--------|
| | Total | Present | Absent |
| 2-5 years | 32 | 12 | 20 |
| 6-12 years | 58 | 30 | 28 |

Graph 10:




Table 11: Duration of Attack (in hours) and WMH in Migraine

| Duration Of Attack (in hours) | Discrete T2/FLAIR hyperintensities | | |
|-------------------------------|------------------------------------|---------|--------|
| | Total | Present | Absent |
| In 24 hours | 34 | 20 | 14 |
| In 12-24 hours | 36 | 16 | 20 |
| In 4-12 hours | 20 | 06 | 14 |

Graph 11:




Table 12: Frequency of Attacks in migraine and WMH

| Frequency of Attacks | Discrete T2/FLAIR hyperintensities | | |
|----------------------|------------------------------------|---------|--------|
| | Total | Present | Absent |
| >1/ week | 26 | 18 | 08 |
| 1/ week | 20 | 12 | 08 |
| 1-2/ month | 16 | 06 | 10 |
| </ year | 0 | 0 | 0 |
| <04/ year | 12 | 02 | 10 |
| 5 - 10 / year | 16 | 04 | 12 |

Graph 12:




Table 13: Intensity of Pain and WMH

| Intensity of Pain | Discrete T2/FLAIR hyperintensities | | |
|-------------------|------------------------------------|---------|--------|
| | Total | Present | Absent |
| Intense | 24 | 14 | 10 |
| Very intense | 24 | 18 | 06 |
| Moderate | 22 | 08 | 14 |
| Mild | 20 | 02 | 18 |

Graph 13:




Table 14: WHM and Severity as per MIGSEV scale in Migraine

| Severity as per | Discrete T2/ FLAIR hyper |
|-----------------|--------------------------|
|-----------------|--------------------------|

| MIGSEV scale | intensities | | |
|--------------|-------------|---------|--------|
| | Total | Present | Absent |
| Grade 1 | 30 | 4 | 26 |
| Grade 2 | 18 | 8 | 10 |
| Grade 3 | 42 | 30 | 12 |

Graph 14:




Table 15: Discrete T2/ FLAIR hyper intensities in MRI Brain of Migraine Patients.

| Discrete T2/ FLAIR hyper intensities | No. of Patients | Discrete T2/ FLAIR hyper intensities | | Discrete T2/ FLAIR hyper intensities | | |
|---|-----------------|--------------------------------------|--------|--------------------------------------|---------|--------|
| | | Present | Absent | Age group | Present | Absent |
| b/l frontal lobes | 2 | 42 | | 15-35 | 28 | 30 |
| left frontal lobe and r pariatal | 2 | 48 | | 36-55 | 14 | 18 |
| B/L frontal lobe and temporal lobe | 2 | 90 | | Total | 42 | 48 |
| b/lpariato occipital lobe | 2 | | | | | |
| b/l frontal, b/lpariatal lobe, | 2 | | | | | |
| b/lfrontoparital lobes | 2 | | | | | |
| b/lparaito occipital lobes | 2 | | | | | |
| b/lpariatal and occipital | 2 | | | | | |
| b/lpariato occipital lobes | 4 | | | | | |
| left occipital lobe and pariatal lobe | 2 | | | | | |
| left basal ganglia | 2 | | | | | |
| left centrum semi ovale and periventricular | 2 | | | | | |
| left frontal lobe and r occipital | 2 | | | | | |
| Lt fronto pariatal lobes | 4 | | | | | |
| periventricular | 8 | | | | | |
| rt frontal and pariatal lobe | 2 | | | | | |
| Total | 42 | | | | | |

Discussion

This study was conducted on 90 patients. Participants of this were evaluated in OPD and the data was collected there. No follow ups were required as all the necessary data was available in the first meet. Out of these 90 patients 24.4% were males and 75.6% patients were female. This coincides with Messoud Ashina^{4,5} study that the gender ratio of migraine patients is 3:1, female male. Other studies have also confirmed that females suffer more from migraine than males. Chaibi et al²⁶ also conclude in their study that there is significant preponderance in females of all the sub types of migraine.

Migraine can be found in patients of all ages. The youngest patient in our study was 17-year-old female and the oldest was 50-year-old male. 34 is the mean age of the patients of this study. We divided our patients into two age groups, 15-35 years and 36-55 years. 53.4% people belonged to the lower age group while as 46.6% belonged to the higher age category. Most of the patients of our study had a long history of migraine. There were no children in our study although Ashina et al have confirmed that migraine affects a good proportion of children too. This may be because children are usually referred to the Pediatric Hospital of our college.

While recording the duration of migraine we found mixed results. 6.6% of the patients had migraine from last two years while as 8.88%, 13.3% and 6.66% patients had reported migraine since 3, 4 and 5 years respectively. 8.88% patients had migraine for 6-7 years. 46.6% patients had migraine complaints since more than 9 years. In our study 53.4% of patients are of the age group of 15-35 years. This indicates that most of the patients report the onset of migraine before the age of 35. Ashina et al are also of the same opinion.

Migraine is actually the acute pain in head. While recording the pain of the patients of the study we used

MIGSEV Pain scale to categorize the severity of pain. 22.2% of the patients suffered from mild pain while as 24.4% suffered from moderate pain. 22.2% patients came under the category of intense pain while as 31.22% came under the category of very intense pain. The inference we could draw from this data is that a good number of patients suffer from intense pain in migraine. Most of these patients with intense pain were young. In young people migraine is the most common disability causing headache.

Patients with migraine often get Nausea. Around 80% of the migraine patients suffer from nausea. Migraine is a very strong trigger of nausea. There are many proposed mechanisms of how migraine triggers nausea but none of them has been established scientifically. We used MIGSEV scale to grade nausea in the patients of our study. 33.3% patients had mild nausea while as 44.4% patients had intense nausea. From participants 11.1% vomited during migraine attack. 11.1% patients from our study had neither nausea nor vomiting. Farooq et al²⁷ conclude that occurrence of nausea in the premonitory phase of migraine is associated with activation of the NTS, dorsal motor nucleus of vague, nucleus ambiguous and the PAG, in the absence of pain, and hence likely represents a primary event.

Migraine patients feel pain attacks which last from 4-72 hours ranging from patient to patient. 22.2 % patients from our study had headache lasting from 4-12 hours. 40% of the patients had acute attack lasting from 12-24 hours. 37.7% patients had an acute headache lasting for more than 24 hours. Most common duration of attack in our patients was 12-24 hours.

In our study, we found that 13.3% patients had less than 4 attacks per year. 17.7% of patients had 5-10 attacks per year. 17.7% patients had 1-2 attacks per months. 22.2%

patients had 1 attack per week. 28.8% of patients had more than one attack per week.

In this study we studied the correlation between nausea/vomiting and white matter hyper intensities. Out of total 90 patients 86 patients suffered from vomiting/ nausea. As discussed above we categorized the nausea into mild, intense and vomiting. 48 patients had suffered from mild nausea and out of these patients, 29.1% patients showed the presence of white matter hyper intensities and in 70.9% patients' white matter hyper intensities were absent. 28 patients in the study had intense nausea and out of these patients 71.4% patients showed white matter hyper intensities on MRI while as 28.6% had no white matter hyper intensities. Among the patients with vomiting 80% patients had white matter hyper intensities while as rest of the 20% had no white matter hyper intensities. From the above statistical analysis, we can infer that the intensity of nausea had a direct relation on the severity of WMH. Patients with white matter hyper intensities have severe nausea/ vomiting. The results of our study coincide with the study carried out by Hasnaoui et al²⁸. This study has also confirmed that migraine related nausea/ vomiting have an association with white matter hyper intensities.

People frequently experience a wave of sensory problems, ranging from nausea and hallucinations to feelings of numbness, before having a seizure or getting a migraine. A warning sign that can persist from a few seconds to an hour before an event, such as a seizure or migraine, occurs, this collection of symptoms is referred to as aura. In our study 44.4% patients with migraine had preceding history of aura while as 55.6% patients did not have such history. The results of our study coincide with the study of Fraser et al²⁹ and Negmet al³⁰.

We divided the patients on the basis of duration of migraine into two groups, patients with migraine from

last 2-5 years and 6-12 years. This division was done to segregate the patients with long history of migraine from those who had recent onset of migraine. 37.5% patients with 2-5-year history of migraine had white matter hyperintensities while as 62.5% patients had no white matter hyperintensities.

On the other hand, in later group, we found that 51.7% patients had white matter hyper intensities while as 48.3% patients had no white matter hyperintensities. This statistical analysis gives the inference that patients with longer history of migraine have more common presence of white matter hyper intensities and coincide with the study conducted by Xie et al³¹.

As already discussed above we divided the patient according to the duration of attack of migraine. Patients were divided into three groups, 1st group with 4-12 hours attack duration, 2nd group with 12-24 hours and 3rd greater than 24 hours duration of attack. Then we analyzed the MRI scans of these patients to check for the white matter hyperintensities. It was found that 30% patients from group one had white matter hyperintensities while as 70% patients from that group showed no white matter hyperintensities.

from group 2nd 44.4% patients had white matter hyperintensities present while as 55.6% patients had no white matter hyperintensities. In the third group 58.8% patients had white matter hyperintensities while as it was absent in remaining 41.2% patients.

From this we can analyze that the occurrence of white matter hyperintensities increases as we go from patients with lower duration of attack to those with longer duration of attack. It was found lowest in the group of patients with lower duration and highest in the group of patients with the longer duration of attack. white matter hyper intensities seem to have an impact on the duration of attack of migraine.

The findings of our study are in agreement with those of the research done by Jasem et al³² and Hasnaoui et al. These investigations have also proven that the risk factors for white matter hyper intensities include advanced age, a prolonged disease course, and frequent migraine attacks. Patients were also categorized on the frequency of attack. We made five groups, 1st group with patients who had less than four attacks per year, 2nd group with 5-10 attacks per year, 3rd group with 1-2 attacks per month, 4th group with one attack per week and 5th group with more than one attack per week.

Such meticulous grouping was done to observe the patients in detail. On the analysis of MRI scans of group 1st, 16.6% patients had white matter hyper intensities while 84.4% did not have white matter hyper intensities. In group 2nd, 25% patients had white matter hyperintensities while as it was absent in 75% patients. In group 3rd, 37.5% patients had white matter hyper intensities and it was absent in 62.5% patients.

From the patients of group 4, white matter hyper intensities was present in 60% patients and absent in 40% patients. In the group 5 patients 69.2% patients showed white matter hyperintensities while as 30.8 patients did not show white matter hyperintensities. Upon analyzing this data, we can infer that white matter hyper intensities increase as we go from the group with lowest frequency to the group with highest frequency of attack.

White matter hyper intensities were found least (16.6%) in the group with less than four attacks a year and highest (69.2%) in the group with more than one attack per week. The results of our study are in correlation with those of the studies done by Jasem et al. and Hasnaoui et al. These investigations have also demonstrated that migraine episodes often, older age, and longer duration of illness are risk factors for white matter hyper intensities.

Patients were divided into four groups on the basis of intensity of pain in migraine. Grouping was done into mild, moderate, intense and very intense, depending on the severity of pain.

When we correlated the MRI scans with this grouping, it was found that in patients with mild pain 10% had white matter hyper intensities while as 90% did not show any presence of it. In patients with moderate pain 36.4% had white matter hyper intensities while as 63.6% did not show presence of it. 58.3% patients with intense pain had white matter hyper intensities while as 41.7% did not have white matter hyper intensities. In the last group of patients with very intense pain 75% had white matter hyperintensities while as it was absent in 25%. Only 10% patients with mild pain had white matter hyperintensities on the other hand 75% with intense pain showed white matter hyper intensities in their MRI scans. This signifies that the severity of pain in migraine has a role in white matter hyper intensities.

Using MIGSEV scale we graded the patients into three groups on the basis of the severity of migraine. Grade I being least severe and grade III being most severe. 13.3% patients of grade I severity had white matter hyper intensities while as 86.7% had no white matter hyper intensities. In patients of Grade II severity 44.4% showed the presence of white matter hyper intensities while as 55.6% did not show the presence of it. In Grade III patients 71.4% had white matter hyperintensities and 28.6% did not.

This statistical analysis shows that in patients with Grade III migraine (very severe) 71.4% had white matter hyper intensities, which is a very significant number. We can infer that as the severity of migraine increases according to MIGSEV Scale, the occurrence of white matter hyper intensities also increases.

The results of our study coincide with the study carried out by Jasem et al and Hasnaoui et al. These studies have also confirmed that older age, longer disease duration and frequent attacks of migraine are risk factor for white matter hyperintensities.

During our study we found some special cases. A 32 male, with migraine history of 5 years was included in this study. He had Grade I severity of migraine as per MIGSEV Scale. He was advised to go for MRI scan. His MRI scan revealed sub arachnoid cyst. However, there were no white matter hyperintensities.

A 47-year-old female came with the complaint of headache. She fulfilled migraine criteria as per ICHD3. She was advised for MRI. Her MRI Scan revealed meningioma and periventricular hyperintensities.

In our study two patients, a 25-year-old female and 19-year-old female, who were fulfilling migraine criteria as per ICHD3. These two patients had a background history of seizure disorder. MRI scan of these patients revealed hyperintensities in frontal and parietal lobes.

Figure legend

Fig 1. Axial FLAIR image of brain showing focal discrete hyper intensity in corona radiata of Right parietal lobe.




Fig 2: Axial FLAIR of brain showing focal white matter hyperintensity in left high frontal lobe.




Fig 3: Axial FLAIR image of brain showing few focal discrete white matter hyperintensities in bilateral frontal lobes.





Fig 4: Axial FLAIR image of brain showing extra axial hyperintense lesion in left occipital lobe in para sagittal location with associated buckling of cortex. Post contrast images revealed heterogeneous enhancement and Dural tail sign (not shown). Imaging features were suggestive of meningioma.



Fig 5: Axial FLAIR Image of brain showing periventricular hyper intensities in bilateral frontal lobes.



Conclusion

In this study we tried to ascertain the Clinico - radiological relation between migraine and white matter hyperintensities in brain. We used MRI as the main tool of investigation. Our study concludes that age, duration of migraine, intensity of pain, nausea/ vomiting, aura, frequency of attacks, duration of attacks, intensity of migraine as per MIGSEV scale have a role in the

presence and absence white matter hyper intensities. Our study found that the presence of white matter hyper intensities has more chances in patients who are aged, have frequent attacks of migraine, have intense pain, feel highly nauseated, have longer duration of attacks and have Grade III migraine on MIGSEV scale.

However further studies are required to further investigate it.

References

1. Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 2018;17:954-76.
2. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB. Cumulative lifetime migraine incidence in women and men. *Cephalalgia* 2008;28:1170-8.
3. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. *Cephalalgia* 2018;38:1-211.
4. Ashina M, Hansen JM, Do TP, Melo Carrillo A, Burstein R, Moskowitz MA. Migraine and the trigemino vascular system — 40 years and counting. *Lancet Neurol* 2019;18:795-804
5. Moskowitz MA. The neurobiology of vascular head pain. *Ann Neurol* 1984; 16: 157-68.
6. Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the Global Campaign against Headache. *J Headache Pain* 2019;20:57.
7. Kruit MC, van Buchem MA, Hofman PA, Bakkers JT, Terwindt GM, Ferrari MD, et al. Migraine as a risk factor for subclinical brain lesions. *JAMA*. 2004; 291 (4): 427-34.

8. Lin J, Wang D, Lan L, Fan Y. Multiple factors involved in the pathogenesis of white matter lesions. *Bio med Res Int.* 2017; 2017: 937-2050. <https://doi.org/10.1155/2017/9372050>.
9. Trauninger A, Leél-Össy E, Kamson DO, Pótó L, Aradi M, Kövér F, et al. Risk factors of migraine-related brain white matter hyperintensities: an investigation of 186 patients. *J Headache Pain.* 2011;12(1):97–103.
10. Toghae M, Rahimian E, Abdollahi M, Shoar S, Naderan M. The prevalence of magnetic resonance imaging hyperintensity in migraine patients and its association with migraine headache characteristics and cardiovascular risk factors. *Oman Med J.* 2015; 30 (3): 203.
11. Zhang Q, Datta R, Detre JA, Cucchiara B. White matter lesion burden in migraine with aura may be associated with reduced cerebral blood flow. *Cephalalgia.* 2017;37(6):517–24.
12. Uggetti C, Squarza S, Longaretti F, Galli A, Di Fiore P, Reganati PF, et al. Migraine with aura and white matter lesions: an MRI study. *Neurol Sci.* 2017;38(1):11–3.
13. Friedman DI, Dodick DW. White matter hyperintensities in migraine: reason for optimism. *JAMA.* 2012;308(18):1920–1.
14. Kurth T, Mohamed S, Maillard P, Zhu YC, Chabriat H, Mazoyer B, Boussier MG, Dufouil C, Tzourio C. Headache, migraine, and structural brain lesions and function: population based Epidemiology of Vascular Ageing-MRI study. *Bmj.* 2011;342.
15. Eggers AE. Migraine white matter hyperintensities and cerebral microinfarcts are silent cryptogenic strokes and relate to dementia. *Med Hypotheses.* 2017;102:1–3.
16. Moschiano F, D'Amico D, Usai S, Grazi L, Di Stefano M, Ciusani E, et al. Homocysteine plasma levels in patients with migraine with aura. *Neurol Sci.* 2008; 29 (1): 173–5.
17. Bautista LE, Arenas IA, Penuelas A, Martinez LX. Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. *J Clin Epidemiol.* 2002;55(9):882–7.
18. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. *Lancet.* 2005; 365 (9455):224–32.
19. Collaboration HS. Homocysteine and risk of ischemic heart disease and stroke. *JAMA.* 2002; 288 (16): 2015–2.
20. Kara I, Sazci A, Ergul E, Kaya G, Kilic G. Association of the C677T and A1298C polymorphisms in the 5, 10-methyltetrahydrofolate reductase gene in patients with migraine risk. *Mol Brain Res.* 2003;111(1–2):84–90.
21. Lea R, Colson N, Quinlan S, Macmillan J, Griffiths L. The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. *Pharmacogenomics.* 2009; 19 (6): 422–8.
22. Menon S, Lea RA, Roy B, Hanna M, Wee S, Haupt LM, et al. Genotypes of the MTHFR C677T and MTRR A66G genes act independently to reduce migraine disability in response to vitamin supplementation. *Pharmacogenomics.* 2012;22(10):741–9.
23. Sachdev P, Parslow R, Salonikas C, Lux O, Wen W, Kumar R, et al. Homocysteine and the brain in midadult life: evidence for an increased risk of leukoencephalopathy in men. *Arch Neurol.* 2004;61(9):1369–76.
24. Dufouil C, Alperovitch A, Ducros V, Tzourio C. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. *Ann Neurol.* 2003; 53 (2): 214–21.

25. Vermeer SE, Van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam scan study. *Ann Neurol*. 2002;51(3):285–9.
26. Chaibi A, Benth JŠ, Tuchin PJ, Russell MB. Chiropractic spinal manipulative therapy for migraine: a three-armed, single blinded, placebo, randomized controlled trial. *Eur J Neurol* 2017; 24: 143-53.
27. El Hasnaoui A, Vray M, Richard A, Nachit-Ouinekh F, Boureau F, Migsev Group. Assessing the severity of migraine: development of the MIGSEV scale. *Headache: The Journal of Head and Face Pain*. 2003 Jun;43(6):628-35.
28. Athar F, Zahid A, Farooq M, Ayyan M, Ashraf M, Farooq M, Naeem F, Badar A, Ehsan M, Hussain A, Ilyas MA. Frequency of migraine according to the ICHD-3 criteria and its association with sociodemographic and triggering factors in Pakistan: A cross-sectional study. *Annals of Medicine and Surgery*. 2022 Oct 1;82:104589.
29. Fraser CL, Hepschke JL, Jenkins B, Prasad S. Migraine Aura: Pathophysiology, Mimics, and Treatment Options. *Semin Neurol*. 2019 Dec;39(6):739-748. doi: 10.1055/s-0039-1700525. Epub 2019 Dec 17. PMID: 31847045.
30. Negm M, Housseini AM, Abdelfatah M, Asran A. Relation between migraine pattern and white matter hyperintensities in brain magnetic resonance imaging. *The Egyptian journal of neurology, psychiatry and neuro surgery*. 2018 Dec;54(1):1-8.
31. Xie H, Zhang Q, Huo K, Liu R, Jian ZJ, Bian YT, Li GL, Zhu D, Zhang LH, Yang J, Luo GG. Association of white matter hyperintensities with migraine features and prognosis. *BMC neurology*. 2018 Dec;18:1-0.
32. Al-Hashel JY, Alroughani R, Gad K, Al-Sarraf L, Ahmed SF. Risk factors of white matter hyperintensities in migraine patients. *BMC neurology*. 2022 Apr 29; 22(1):159.